2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148492
    Mrgx2 antagonist-2 2767111-67-9 98%
    Mrgx2 antagonist-2 is a Mrgx2 antagonist (Example 123 in reference patent) with a pIC50 of 8.6. Mrgx2 antagonist-2 can be used in the research of MrgX2 -mediated diseases or disorders.
    Mrgx2 antagonist-2
  • HY-14852S
    Tafamidis-d3 98%
    Tafamidis-d3 is deuterium labeled Tafamidis. Tafamidis is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. Tafamidis inhibits amyloidogenesis.
    Tafamidis-d3
  • HY-148533
    β2AR agonist /M-receptor antagonist-1 2772700-36-2 98%
    β2AR agonist /M-receptor antagonist-1 is a potent dual muscarinic antagonist/beta 2 agonist (MABA). β2AR agonist /M-receptor antagonist-1 potently relaxes either Carbachol (HY-B1208)-induced contraction, in the absence (MABA) or presence of Propranolol (M3; HY-B1208), or Histamine (HY-B1204)-induced contraction (β2).
    β2AR agonist /M-receptor antagonist-1
  • HY-148535
    Calpain Inhibitor XI 145731-49-3 98%
    Calpain Inhibitor XI is a reversible covalent inhibitor of calpain-1. Calpain Inhibitor XI can be used for the research of neurodegenerative disorders.
    Calpain Inhibitor XI
  • HY-148547
    q-FTAA 1352477-22-5 98%
    q-FTAA binds to Aβ1-42 fibrils with EC50 values of 330-630, 300-500 nM for Aβ1-42 fibrils, alzheimer's disease PIB binding complex (ADPBC) , respectively. q-FTAA has the potential for the research of Alzheimer's disease (AD).
    q-FTAA
  • HY-148548
    p-HTAA 1175142-38-7 98%
    p-HTAA is a pentamer hydrogen thiophene acetic acid. p-HTAA specifically labels Aβ deposits in the mice living brain.
    p-HTAA
  • HY-148558
    P2X7 receptor antagonist-3 1627900-92-8 98%
    P2X7 receptor antagonist-3 is a potent P2X7 receptor antagonist with P2X7R IC50 values of 4.2 nM in humans and 6.8 nM in rats.
    P2X7 receptor antagonist-3
  • HY-148611
    NSC339614 potassium 1135037-53-4 98%
    NSC339614 potassium is a selective GluN1/GluN2C and GluN1/GluN2D receptor enhancer with the activity of enhancing neuronal responses to specific NMDA receptors. NSC339614 potassium can selectively enhance the signaling of GluN1/GluN2C and GluN1/GluN2D receptors without affecting other NMDA receptors. The mechanism of action of NSC339614 potassium does not compete with agonists of L-glutamate or glycine, nor does it depend on membrane potential. The activity of NSC339614 potassium depends on the specific structure of the agonist ligand binding domain, showing its potential as a novel pharmacological agent for studying the function of NMDA receptor subtypes and providing new lead compounds for a variety of neurological diseases.
    NSC339614 potassium
  • HY-148717
    NSC363998 free base 159357-82-1 98%
    NSC363998 (free base) is an orally active compound. NSC363998 (free base) can suppress rCGG90 induced neurotoxicity. NSC363998 (free base) can be used for the research of neurodegenerative disorder such as Fragile X associated tremor/ataxia syndrome (FXTAS).
    NSC363998 free base
  • HY-148718
    4-Chloro Trazodone hydrochloride 1263278-77-8 98%
    4-Chloro Trazodone hydrochloride is an isomer of Trazodone hydrochloride (HY-B0478). Trazodone hydrochloride is an antidepressant belonging to the class of serotonin receptor antagonists and reuptake inhibitors for treatment of anxiety disorders.
    4-Chloro Trazodone hydrochloride
  • HY-148828
    LSP-GR3 1235945-37-5
    LSP-GR3 is a novel chemically-modified RNA oligonucleotides, called splice modulating oligomers (SMOs), which potently and specifically modulate GluR alternative splicing to GluR3-flip expression throughout the CNS.
    LSP-GR3
  • HY-148866
    Cavα2δ1&NET-IN-3 2143584-82-9 98%
    Cavα2δ1&NET-IN-3 (example 216) is an inhibitor of the subunit α2δ of voltage-gated calcium channels (VGCC) and noradrenaline transporter (NET). Cavα2δ1&NET-IN-3 has Kis of 100-500 nM for human α2δ-1 subunit of Cav2.2 calcium channel and NET, respectively.
    Cavα2δ1&NET-IN-3
  • HY-148909
    Isopropyl dodec-11-enylfluorophosphonate 623114-64-7 98%
    Isopropyl dodec-11-enylfluorophosphonate (IDEFP) is an organophosphorus ester that antagonizes the central cannabinoid receptor (CB1) and inhibits FAAH with similar potencies (IC50 = 2 nM).
    Isopropyl dodec-11-enylfluorophosphonate
  • HY-14895B
    Fabomotizole di(hydrochloride) 189638-30-0 98%
    Fabomotizole dihydrochloride is an anxiolytic agent. Fabomotizole dihydrochloride produces anxiolytic and neuroprotective effects without any muscle relaxant actions.
    Fabomotizole di(hydrochloride)
  • HY-149012
    AChE/hCA I/II-IN-1 2049681-10-7 98%
    AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of AChE/Hca with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes.
    AChE/hCA I/II-IN-1
  • HY-149014
    OX2R-IN-1 2639148-08-4 98%
    OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life.
    OX2R-IN-1
  • HY-149065
    D-685 2893801-00-6 98%
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
    D-685
  • HY-149087
    MR2938 1044870-65-6 98%
    MR2938 is a potent AChE inhibitor, with an IC50 of 5.04 μM. MR2938 also suppresses NO production obviously (IC50 = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.
    MR2938
  • HY-149090
    AChE/BuChE/MAO-B-IN-2 98%
    AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent AChE/BuChE inhibitor and showed good blood brain barrier (BBB) permeability in vitro with an IC50 value of 5.3 μM, 12.4 μM, 1.9±0.08 μM, for AChE, BuChE, huMAO-B, respectively. AChE/BuChE/MAO-B-IN-2 (compound 4b) can inhibit excess AChE/BuChE in Alzheimer's disease (AD) brain. AChE/BuChE/MAO-B-IN-2 (compound 4b) can be used in anti-Alzheimer's research.
    AChE/BuChE/MAO-B-IN-2
  • HY-149097
    ITH12711 3042876-07-0 98%
    ITH12711 is a PP2A ligand. ITH12711 is able to cross the blood-brain barrier (BBB). ITH12711 exerts neuroprotection via restoration of PP2A-phosphatase activity.
    ITH12711
Cat. No. Product Name / Synonyms Application Reactivity